

ALZHEIMER EUROPE NEWSLETTER

TABLE OF CONTENTS

01	Welcome
02	Alzheimer Europe
04	Alzheimer Europe networking
05	EU projects
09	European Alzheimer's Alliance
10	EU developments
11	Policy watch
14	Science watch
17	Members' news
20	Living with dementia
21	Dementia in society
21	New publications and resources
22	Education
22	AE calendar
23	Conferences

HIGHLIGHTS IN THIS ISSUE

1 February: We respond to proposed EU mental health initiative	2
14 February: Global Call on Long-term Care and Ageing is launched	11
28 February: 41st edition of "Dementia in Europe" magazine is out!	2
28 February: Registrations open for our Annual Conference #33AEC	3

WELCOME



I am delighted to invite you all to register for the 33rd Alzheimer Europe Conference in Helsinki, Finland. Our conference is taking place from 16 to 18 October under the banner "New opportunities in dementia care, policy and research". Our special Early Bird registration fees are available until 30 June. I also invite you to submit abstracts, as the call for abstracts is still open, until 30 April. If you would like to view videos from last year's event in Bucharest, these are available online, via our website and YouTube channel and you can also read about the Bucharest conference in a special section featured in our newly-published Dementia in Europe magazine. The new issue is available on our website and is full of interesting articles on the latest developments in the field of dementia, at a national and European level.

Alzheimer Europe has responded to a European Commission call for evidence on its proposed initiative taking a comprehensive approach to mental health. The initiative was announced by European Commission President Ursula von der Leyen during her State of the EU speech in November 2022. As well as welcoming the decision to act in this area and acknowledging the context approach of the initiative within the scope of existing EU programmes and those of the World Health Organization (WHO) and the Sustainable Development Goals, we also highlighted issues needing attention. These include: the need to ensure the initiative more closely reflects the work of the WHO in mental health, to include dementia; the

omission of carers, despite the impact of caregiving roles on mental health, especially during the pandemic; the scope of the proposed targets and indicators for the initiative being too narrow.

More on all of the above can be found in the Alzheimer Europe section of this newsletter.

I have been hugely impressed with the quantity (and quality!) of global and national campaigns and initiatives that have been launched recently. The Global Ageing Network issued a "Call to the Governments of the World on Long-term Care and Ageing" demanding urgent attention to and reform of long-term care systems for older people; the WHO is seeking feedback on its Global Campaign to Combat Ageism via a new survey; Slovenia's Ministry of Health launched a campaign, to raise awareness around dementia, cancer and mental health and to tackle a variety of addictions; as part of its National Dementia Strategy, the Netherlands launched a large-scale collaboration called "TAP-dementia" (Timely, Accurate and Personalized diagnosis of dementia); and last but not least, in Finland, a special "dementia panel" was organised at the Finnish Parliament, giving people with dementia and carers the opportunity to put questions to a panel of MPs.

On the EU project front, my colleagues and I have, as always, been busy with a variety of meetings, conferences and consultations this month, including the General Assembly of the ADIS project which took place in Tel Aviv, Israel and online.

I hope you enjoy our newsletter!

Jean Georges
Executive Director

ALZHEIMER EUROPE

1 February: Alzheimer Europe responds to call for evidence on proposed mental health initiative



Alzheimer Europe has responded to a European Commission call for evidence on a proposed initiative of a comprehensive approach to mental health. The initiative had been announced by European Commission President Ursula von der Leyen during her State of the EU

speech in November 2022.

The initiative will set out:

- How action at EU level can help promote good mental health and prevent, mitigate and respond to mental health challenges
- How mental health considerations should be factored into a wide variety of resilient EU and national policies for the benefit of people across the EU.

In its response, Alzheimer Europe welcomed the Commission's decision to act in this area and acknowledged the context approach of the initiative within the scope of the EU's existing programmes and those of the World Health Organization (WHO) and the Sustainable Development Goals (SDGs).

However, the response also highlighted some potential issues, which were felt to need specific attention in the development of the initiative, including:

- Encouraging the Commission to ensure that the initiative more closely reflects the work of the WHO in mental health, to include dementia
- Highlighting the omission of carers despite the impact of caregiving roles on mental health, especially during the pandemic
- Noting that the scope of the proposed targets and indicators for the initiative are too narrow and do not cover goals which should be part of the initiative.

Alzheimer Europe's full response to the call for evidence can be found at:

<https://www.alzheimer-europe.org/policy/positions/european-commission-mental-health-initiative>



Sponsors of the month

Alzheimer Europe would like to express its gratitude to two sponsors for its 2023 activities.

Read more about sponsorship opportunities here:
<https://www.alzheimer-europe.org/about-us/governance/finances/2022-sponsorship-opportunities>



28 February: Alzheimer Europe publishes 41st edition of its "Dementia in Europe" magazine

It is with great pleasure that we introduce the 41st edition of our Dementia in Europe magazine. The latter part of 2022 was full of activity and the beginning of 2023 has continued apace!

We open the Alzheimer Europe section by recounting our European Parliament lunch debate held in September 2022, which examined the role of artificial intelligence (AI) in dementia research. We are incredibly grateful to Sirpa Pietikäinen MEP (Finland) for chairing the session.

Alzheimer Europe has recently launched a number of important publications, which are presented in the following two articles. The first of these is the Dementia in Europe Yearbook 2022, which focused on employment and social protection for people with dementia and their carers. The second article looks at the two new guides which have been produced, one on ethical and respectful communication about dementia and the other on sex, gender and sexuality in the context of dementia. The 32nd Alzheimer Europe Conference (32AEC) in Bucharest, Romania, saw many changes for our organisation, which we cover in the following articles. Firstly, we introduce the new Alzheimer Europe Board, after which I share my thoughts on the future of the organisation as its new Chairperson, and then we present the new European Working Group of People with Dementia (EWGPWD) for the 2022-2024 term. The collaboration between Alzheimer Europe and Roche for World Alzheimer's Day is the subject of our next article, looking at the "What makes you, you" campaign. Still on the theme of collaboration, the new



year brings three new projects: ADIS, eBRAIN-Health and PatternCog, in which Alzheimer Europe is delighted to be involved. We wrap up this section by looking at the winners and runners up of our inaugural Anti-Stigma Award, presented at 32AEC, with their inspiring work to lessen the stigma associated with dementia.

Moving to the Policy Watch section, we are delighted to feature an interview with the European Commissioner for Jobs and Social Rights, Nicolas Schmit, on the European Care Strategy and what this means for people living with dementia and carers. We are also pleased to share an interview with the former President of Slovenia, Borut Pahor, with whom our colleagues in Spominčica - Alzheimer Slovenija worked closely to prioritise dementia as a political matter and to make progress on a new dementia strategy. At a European level, we report on the European Day of Persons with Disabilities conference, hosted by the European Commission and the European Disability Forum, in which Alzheimer Europe was delighted to participate, together with a number of members of the EWGPWD. We then hear from colleagues in the World Health Organization (WHO) Europe on their ongoing work on mental health and dedicated work-stream on older person's mental health, whilst colleagues from the Organisation for Economic Cooperation and Development (OECD) share views on key areas for the future of dementia policy from diagnosis to end-of-life. In the final article of the section, we hear from the Hague Convention following their recent Special Commission on the Convention for the Protection of Vulnerable Adults.

We open the Dementia in Society section with an interview with the Mayor of Brussels, Philippe Close, who recently signed a charter pledging that the city will become dementia friendly – a most welcome development, especially since Brussels is the capital of Europe, the headquarters of the European institutions and also the location of many Alzheimer Europe meetings!

In the following article, Ukrainian charity Nezabutni ("Unforgettable"), a new member of the Alzheimer Europe family, shares details of the ongoing challenges faced by persons living with dementia, as a consequence of the Russia's invasion of the country and the changes the charity has made in incredibly difficult circumstances and how they continue to offer support in the most difficult circumstances. Our next article examines the recent research developments in disease-modifying therapies for Alzheimer's disease. We interviewed Nicolas Villain, who has published two reviews on anti-amyloid immunotherapies, and asked three other experts in the field for their perspectives on the recent phase III results of lecanemab. From there we move on to the Older Adults Mental Health Awareness week, coordinated by the International Psychogeriatric Association, which included the perspective of a person living with dementia, input from Alzheimer associations, as well as the involvement of the Chair of the European Alzheimer's Alliance, Sirpa Pietikäinen MEP (Finland). In the final article in this section, Kevin Quaid, Vice-Chairperson of the EWGPWD, tells us about how living with Lewy body dementia has impacted on his sleep.

In the final section, we revisit our Annual Conference, 32AEC, in Bucharest, Romania, including the plenary sessions, special symposia and the involvement of the INTERDEM network. It was wonderful to be able to attend the conference in person after two years of online conferences. We hope you enjoy reading our magazine!

Alzheimer Europe is grateful for the support of its corporate sponsors, without whom the Dementia in Europe magazine would not be possible.

You can download the 41st edition of our magazine, here: https://www.alzheimer-europe.org/sites/default/files/2023-02/dementia_in_europe_magazine_issue_41_february_2023.pdf

It is also possible to order paper copies of the magazine, via the website link.

**Help us give a voice to people
with dementia**

Donate



28 February: Registrations are open for the 33rd Alzheimer Europe Conference #33AEC!

We are delighted to invite you to register for the upcoming 33rd Alzheimer Europe Conference (#33AEC), which will take place in Helsinki, Finland from 16 to 18 October 2023, under the banner "New opportunities in dementia care, policy and research" and in collaboration with Muistiliitto, the Alzheimer Society of Finland.

This event will be mainly in-person but will include some broadcast elements such as plenary sessions, and other carefully selected parallel sessions and symposia to allow those still unable to travel to participate from the comfort of their home or office. As in previous years, we hope that #33AEC will be a great networking opportunity, bringing together people with dementia, their carers and supporters, volunteers and staff of Alzheimer associations, policymakers, health and social care professionals, researchers, academics and industry representatives from across Europe and beyond.

Take advantage of the early bird registration fees until 30 June 2023 to attend in-person in Helsinki, or virtually. Register with the early bird rates and benefit from the reduced in-person registration fee of EUR 400 instead of EUR 500. A 30% discount is available for participants from low and middle income countries. Special rates are also available for people with dementia, students and member associations of Alzheimer Europe. Click here for more information about in-person registration fees:

<https://www.alzheimer-europe.org/conferences/2023-helsinki/registration-fees-person-attendance>

Click here for more information about virtual attendance fees:

<https://www.alzheimer-europe.org/conferences/2023-helsinki/registration-fees-virtual-attendance>

Click here to register: <https://www.alzheimer-europe.org/conferences/2023-helsinki/online-conference-registration>

Our call for abstracts is also open until 30 April:

<https://www.alzheimer-europe.org/conferences/2023-helsinki/abstract-submission>



**Abstract submission and
early bird registration open!**



33rd Alzheimer Europe Conference
New opportunities in dementia care, policy and research
Helsinki, Finland
16 - 18 October 2023 #33AEC

ALZHEIMER EUROPE NETWORKING

From 31 January to 1 February (Tel Aviv, Israel and online), Soraya, Chris and Jean attended the ADIS project General Assembly.

On 1 February, Ana, Cindy and Jean attended a Luxembourg National Research Fund (FNR) webinar on project reporting.

On 1 February, Dianne attended the MinD Network meeting.

On 2 February, Cindy attended an extraordinary General Assembly Meeting for the AI-Mind project.

On 5 February, Jean met with Alzheon.

On 7 February, Dianne attended a meeting with researchers interested in continence care.

On 7 February, Soraya and Ana attended an online consultation with the ADIS Advisory Board.

On 8 February, Daphné and Dianne attended an online consultation with the eBRAIN-Health Public and Patient Advisory Group.

On 10 February, Jean met with BioArctic.

On 10 February, Gwladys met with Teamwork.

On 13 February, Gwladys met with Lufthansa Group to support the 33rd Alzheimer Europe Conference.

On 13-14 February (Stockholm, Sweden), Jean attended the High Level Meeting on Active and Autonomous Ageing of the Swedish EU Presidency.

On 15 February, Gwladys met with Suomen Videoviestintä about the 33rd Alzheimer Europe Conference audio-visual (AV) needs.

On 15 February, Dianne and Ana had a meeting with a sub-group of the European Working Group of People with Dementia (EWGPWD) on the topic of risks and benefits of developing drugs.

On 16 February, Dianne attended the INTERDEM Academy Advisory Board meeting.

On 16 February, Soraya attended an online coordination meeting of environmental non-governmental organisations (ENGOS).

On 17 February, Ana and Dianne had a meeting with people with mild cognitive impairment (MCI) on the topic of risks and benefits of developing drugs.

On 17 February, Jean attended a meeting of the European Alzheimer's Disease Consortium on amyloid therapies.

On 20 February, the Alzheimer Europe Board met.

On 20 February, the Board of the Alzheimer Europe Foundation met.


On 21 February (Brussels, Belgium), Iva, Rosário and Jean attended the consensus conference of the RECAGE (REspectful Caring for AGitated Elderly) project.

On 24 February, Kate met with publishing house Antilope de Bie to discuss the Dementia in Europe magazine.

On 28 February, Alzheimer Europe organised an Alzheimer's Association Academy on "Understanding clinical trials".

EU PROJECTS

30 January: eBRAIN-Health project hosts a General Assembly meeting, convening representatives of 20 partner institutions



eBRAIN-Health

At the end of January, the eBRAIN-Health project hosted one of its quarterly General Assembly meetings. Attended by representatives of the 20 partners in this Horizon Europe-funded project, these meetings act as a forum for high-level updates from the various eBRAIN-Health workstreams.

The eBRAIN-Health project aims to create an infrastructure for the lawful and transparent sharing of brain data, with the goal of building virtual representations of the brain to improve research and clinical management for brain conditions such as Alzheimer's disease. AE is involved in several work packages of the project, conducting activities related to communication and dissemination, public involvement, and ethics. The Coordinator of the eBRAIN-Health project, Prof. Petra Ritter, started the meeting by presenting an overview of project progress. The leading partners of each work package presented what they have achieved since the last General Assembly meeting in October 2022, and their priorities for the upcoming months. These activities encompass technical development of the eBRAIN-Health research platform, contracting and GDPR compliance work for clinical research data, and scoping work on public outreach and engagement. Partners also discussed the creation of the Scientific, Technical and Ethical Advisory Board for eBRAIN-Health, which will include international experts who will provide high-level feedback and guidance for the project. Drawing the meeting to a close, Prof. Ritter thanked attendees for their active engagement and discussions.

30 January: Members of European Working Group of People with Dementia take part in EPND project consultation to discuss reciprocity in research and the barriers to Public Involvement



On 30 January, the members of the European Working Group of People with Dementia attended an online consultation organised in the context of the European Platform for Neurodegenerative Diseases (EPND) project. The consultation was facilitated by Dianne Gove (Director for Projects), Ana Diaz (Project Officer) and Daphné Lamirel (Project Officer). Cindy

Birck (Project Officer) also joined the meeting to provide some technical support. The discussions were split into smaller groups and revolved around the concept of reciprocity in public involvement and other research activities. Participants also provided their views on and experiences of the barriers and facilitators to participating in public involvement activities and other research activities (e.g. a clinical trial) for people with dementia. All participants provided very insightful contributions to the discussions – this input will be used to develop guidelines for researchers in the EPND project.

31 January: ADIS partners meet for General Assembly meeting in Tel Aviv, Israel



From 31 January to 1 February (Tel Aviv, Israel and online), partners from the ADIS project met for their biannual General Assembly meeting. The “Early Diagnosis of Alzheimer’s Disease by Immune Profiling of Cytotoxic Lymphocytes and Recording of Sleep Disturbances” – short ADIS project – is a JPNF-funded 1.3 million EUR three-year project, coordinated by Fraunhofer SCAI. The goal of ADIS is to thoroughly characterise the role of peripheral blood cytotoxic lymphocytes as potential markers for the early prediction of Alzheimer’s disease, and to investigate the influence of digitally assessed sleep disturbances on these markers.

The project meeting kicked off with opening remarks by project coordinator Prof. Holger Fröhlich (Fraunhofer SCAI), as well as meeting host and project collaborator Prof. Uri Nevo (University of Tel Aviv) welcoming all participants and providing an overview of the agenda for the two-day meeting.

Next, Vanessa Lage-Rupprecht (Fraunhofer SCAI), provided an overview of the latest work with regard to project management and the progress in terms of reporting, noting that all of the tasks are on track. This was complemented by Christophe Bintener (Alzheimer Europe) with an introduction to the work done for the dissemination and communication tasks for ADIS, including an introduction to the brand identity, website, project channels, Alzheimer Europe’s network that will be leveraged to support the visibility of the research efforts, concluding with an overview of future work such as a project clip.

After that, Raquel Sánchez-Valle (Fundació Clínic per a la Recerca Biomèdica) provided an update with regard to the ongoing work focussed on experimental approaches as well as data collection. The ethics approval was already received in May

2022, and 15 participants have been enrolled in the study. Raquel then provided an overview of the sleep data that is being collected, this was followed by a discussion focused on the material transfer plans among study partners.

Hereafter, Prof. Anat Mirelman (Tel-Aviv Medical Center) gave a special lecture on markers in neurodegenerative diseases, introducing the current state of knowledge as well as future research directions before the lunch break.

The afternoon focused on an overview of plans for data analysis and modelling presented by Sophia Krix (Fraunhofer SCAI), where she introduced research questions that are focused on the use of data from pre-existing studies and the use of Artificial Intelligence to disentangle the dependencies between variables to better understand Alzheimer's disease and how that could be set up through an innovative modelling approach.

The second day kicked off with a special lecture by Prof. Michal Schwartz (Weizmann Institute of Science) who spoke about the role of the immune system in brain function and repair.

Last but not least Soraya Moradi-Bachiller (Alzheimer Europe) spoke about the setup of an Advisory Board comprised of five people (living with Mild Cognitive Impairment due to Alzheimer's disease) from Spain who participate in Spanish consultations as well as members of the European Working Group of People with Dementia who participate in English consultations. The consultations currently focus on the informed consent process in research projects with the aim to lead to the development of guidelines on how to design a participant information sheet and informed consent form for research studies on Alzheimer's disease in a user-friendly and understandable way. These guidelines are aimed at researchers. After that, partners discussed a potential publication and held round table discussions. The meeting was then formally closed by Holger Fröhlich who thanked all attendees for their contributions and the lively scientific exchange.

Learn more about the project: www.adis-project.eu

1 February 2023: LETHE project includes first patient in study and starts 2-year intervention trial



LETHE (A personalized prediction and intervention model for early detection and reduction of risk factors causing dementia, based on AI and distributed Machine Learning) is a four-year project.

LETHE aims to provide a data-driven risk factor prediction model for older individuals at risk of cognitive decline building upon big data analysis of cross-sectional observational and longitudinal intervention datasets from 4 clinical centres in Europe.

Project partners are pleased to share that the first participant of the 2-year intervention trial has been recruited. The aim is to establish a digital-enabled intervention for cognitive decline prevention based on the evolution of a successful protocol (FINGER) evolving into an ICT based preventive lifestyle

intervention through individualized profiling, personalized recommendations, feedback and support (FINGER 2.0), well targeted on a population stratified by cost-effective biological biomarkers. The LETHE solution will be tested in a feasibility study validating the achieved improvements. Find out more about the project:

<https://www.lethe-project.eu/>

7 February: Members of the ADIS advisory board discuss data management and confidentiality in the project



On 7 February, Cristina, Kina, García, Ricard and Pilar (members of the ADIS-advisory board (ADIS-AB), and their supporters, met online for the second consultation in the context of Public Involvement activities of the ADIS project. As in the first consultation, this meeting focused on the informed consent process in research projects on Alzheimer's disease.

Members of the ADIS-AB were asked to provide their perspectives on data management and confidentiality in research studies and how these topics are presented in the information sheet and informed consent form of the ADIS project. Together with the feedback gathered during the first consultation on 24 January (about terminology, tone and content), the ideas collected during this meeting will help Alzheimer Europe to develop guidelines for researchers on how to design a participant information sheet and informed consent form for research studies on Alzheimer's disease.


The consultation was lively, with all the members actively providing valuable feedback. The discussion was facilitated by AE Projects Officers Soraya Moradi-Bachiller and Ana Diaz and also attended by neuropsychologist Andrea del Val Guardiola (Fundació Clínic per a la Recerca Biomèdica, Spain) and Jesús Rodrigo (Confederación Española de Alzheimer, Spain).

For more information about the ADIS project, please visit:

<https://www.adis-project.eu/>



8 February: The eBRAIN-Health Public and Patient Advisory Group members gather for their first online consultation!




On Wednesday 8 February, members of the eBRAIN-Health Public and Patient Advisory Group, Lilo (Germany), José (Spain), Eileen (UK) and Julie (UK), met online for their first consultation.

The meeting was also attended by Leon Stefanovski (Charité University Berlin) and Dianne Gove (Director for Projects at Alzheimer Europe), and facilitated by Daphné Lamirel (Project Officer at Alzheimer Europe). The last member of the group, Fernando (Spain), sent his apologies but provided some written feedback which was presented and discussed as part of the meeting.

The members presented their varied backgrounds as well as their motivations and enthusiasm to join the PPAG. All expressed a wish to have their voices heard and contribute to improving research in the field of dementia.

The meeting included a presentation of the overall project and a discussion of the concept of digital brain twins. In the second part of the meeting, members gave their views on issues related to the ethics and trustworthiness of digital brain twins. Conversations revolved around the use of digital brain twins in the clinic, privacy, transparency and public expectations. All participants provided very valuable insights and opinions – all of which will serve to inform the eBRAIN-Health Ethical and Legal Framework. The next meeting of the Group is due to take place in March and will continue its focus on the ethics of digital brain twins as well as on AI use in medical research more broadly.

17 February: EU-funded project Alzheimer's Detect & Prevent (ADDP) concludes successfully



The three-and-a-half-year Alzheimer's Detect & Prevent project (ADDP), funded with EUR 3.5 million by the EU, commenced in November 2018,

with the objective to develop and validate digital solutions for early detection and prevention of Alzheimer's disease. In other words, to create ways to identify people early, before Alzheimer's disease (AD) has progressed far and manifested with symptoms, to allow for prompt prevention efforts. The project consisted of a consortium of partners including Brain+ A/S, University of Oxford, University of Nottingham, University of Aarhus, Aarhus University Hospital, the European Brain

Council and Alzheimer Europe. Read more at <https://www.addp.eu>

Kim Baden-Kristensen, CEO & Co-founder of Brain+ said: "The 'Alzheimer's Detect & Prevent' project has been our biggest and most ambitious innovation project to date and has resulted in very valuable additions to our technology and science base that our future products will be based on. Working with top academics, clinicians and patient organisations in this field is both an honour and a pleasure, and we are happy to already be continuing these partnerships in new projects."

The project developed and tested two digital technologies:

- The Starry Night cognitive test, and
- Computerized Cognitive Training games.
- Two clinical trials have been conducted by the University of Oxford ([press release](#)) and the University of Nottingham ([press release](#)), and a third is being finalised by the University of Aarhus, to test these technologies. The concluded trials showed promising feasibility of both technologies.

Read more details about the two technologies, the trials, the future development plans, here: <https://www.alzheimer-europe.org/news/eu-funded-project-alzheimers-detect-prevent-addp-concludes-successfully>

For further information, contact CEO and co-founder of Brain+, Kim Baden-Kristensen, tel.: (+45) 31393318, email: kim@brain-plus.com

23 February: RADAR-AD investigator speaks about digital biomarkers in personalised healthcare at Luxembourg Center for Systems Biomedicine

Prof. Dr Holger Froehlich (Fraunhofer SCAI), who is leading the RADAR-AD project's work stream on functional domains and modelling, recently gave a talk on the project at the Luxembourg Centre for Systems Biomedicine (LCSB). Dr Froehlich presented his work on RADAR-AD and talked about the potential of digital devices and sensor technologies to enable objective and continuous monitoring of disease symptoms. Read more, here:

<https://www.radar-ad.org/newsroom/radar-ad-investigator-speaks-about-digital-biomarkers-personalized-healthcare-luxembourg>



23 February: Chris Roberts, member of RADAR-AD Patient Advisory Board and Chairperson of European Working Group of People with Dementia, speaks at session on patient involvement



The European Federation of Pharmaceutical Industries and Associations (EFPIA) recently organised an online workshop entitled “Enhancing patient-centric outcome measures and clinical trials with Digital Health Technologies”. This was a multi-stakeholder event where participants were able to discuss requirements for Digital Health Technologies (DHT) in clinical trials, including the development of digital endpoints. Chris Roberts, member of the RADAR-AD Patient Advisory Board and Chairperson of the European Working Group of People with Dementia shared his experience of and vision for patient involvement in dementia research. Read more, here:

<https://www.radar-ad.org/newsroom/chris-roberts-member-radar-ad-patient-advisory-board-and-chair-european-working-group>

24 February: AMYPAD features in the CORDIS "Results in Brief" section



The Amyloid imaging to prevent Alzheimer's disease (AMYPAD) consortium was a collaborative research initiative aiming to improve the understanding, diagnosis and management of AD through the utilisation of β -amyloid PET imaging. AMYPAD was funded by the Innovative Medicines Institute (now known

as the Innovative Health Initiative) for a period of 6 years, until 30 September 2022.

AMYPAD was selected for publication in the “Results in Brief” section of the European Commission's CORDIS website. The article includes some insights that emerged during the project and highlights the collaborative work between academic and industrial partners.

“We have had a very fruitful partnership between the industry and academic partners and we are very proud that both of these large clinical studies were completed within the project timeframe and are now yielding results that could directly impact patients in the clinic,” said Gill Farrar, EFPIA lead for the


project. While the project may be finished, the consortium's work continues. The AMYPAD dataset of over 3.500 amyloid PET scans covering the entire Alzheimer's disease continuum will become available to the global research community soon.

“We are finalising procedures to further unlock the wealth of the data we generated. We hope that the AMYPAD data will be a significant asset to worldwide research in the dementia field.”, said Frederik Barkhof, AMYPAD project coordinator. You can read the article published on the CORDIS website here:

<https://cordis.europa.eu/article/id/442894-advancing-imaging-s-role-in-understanding-alzheimer-s-disease>

24 February: Join the webinar on how EU projects are leading artificial intelligence technologies to serve patient needs and improve brain health

The future environment we live in will be largely determined by how we approach artificial intelligence (AI) to improve the health and longevity of citizens. In this context, people and healthcare stakeholders should be able to profit from AI benefits while feeling secure and protected in order to provide better care and cure to patients living with chronic health conditions.



Within this regard, the AI4Brain Community of Interest (CoI) Webinar Series initiated by the H2020 funded projects LETHE and ALAMEDA, will bring together leading research and innovation initiatives, digital health experts, patient representatives and policymakers to exchange best practices and steer collective reflection over what is next for the European Union when it comes to AI applications in personalised brain health.

The 1st Webinar arranged in this frame gathers leading AI practitioners and clinicians for an experience-sharing debate around the challenges and the most promising tools in digital brain health. The Webinar specifically focuses on the latest AI applications to improve the understanding of the course of neurodegenerative diseases, such as Alzheimer, Parkinson's Diseases and MS.

Neurodegenerative disorders are a type of neurological illness that causes gradual loss of neuronal structures and functions, thus manifesting with hard to detect early onset signs and a progressive clinical course, resulting in profound functional impairments and a burdensome impact on quality of life and wellbeing.

The clinical symptoms of neurodegenerative diseases are complicated and differ substantially across individual patients in terms of type, severity, and frequency. Faced with such a large inter-individual variability, it is a major challenge for

clinicians to make an accurate and timely diagnosis, prognosis, and management plan for a given patient.

The Webinar will take place online on the 3 March 2023, 13:00 – 14:30 CET. Register now:

<https://centralntua.webex.com/weblink/register/r7e35e3afce65e49041fddffb14b15952>



Follow us on Twitter

EU project acknowledgements



innovative
medicines
initiative



A number of the projects in which Alzheimer Europe is a project partner receive funding from Horizon2020 or from the Innovative Medicines Initiative, Innovative Medicines Initiative 2, and the Innovative Health Initiative Joint Undertakings. The Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. The projects in this newsletter are:

ADDP – grant agreement 820636

AMYPAD – grant agreement 115952

eBRAIN-Health – grant agreement 101058516

EPND – grant agreement 101034344

LETHE – grant agreement 101017405

RADAR-AD – grant agreement 806999



Luxembourg National
Research Fund



JPND
research
EU Joint Programme – Neurodegenerative Disease Research

ADIS - This project is supported by the Luxembourg National Research Fund (INTER/JPND21/15741011/ADIS) under the aegis of the EU Joint Programme - Neurodegenerative Disease Research (JPND) - www.jpnd.eu

Members of the European Alzheimer's Alliance



Currently, the total number of MEPs in the Alliance stands at **89**, representing **26** Member States of the European Union and six out of seven political groups in the European Parliament. Alzheimer Europe would like to thank the following MEPs for their support of the European Alzheimer's Alliance (EAA):

Austria: Claudia Gamon (Renew Europe); Monika Vana (Greens/EFA). **Belgium:** Frédérique Ries (Renew Europe); Kathleen van Brempt (S&D); Hilde Vautmans (Renew Europe). **Bulgaria:** Radan Kanev (EPP); Andrey Kovatchev (EPP); Ilhan Kyuchyuk (Renew Europe); Tsvetelina Penkova (S&D); Sergei Stanichev (S&D). **Croatia:** Biljana Borzan (S&D); Tonino Picula (S&D). **Cyprus:** Costas Mavrides (S&D). **Czech Republic:** Tomáš Zdechovský (EPP). **Denmark:** Margrete Auken (Greens/EFA); Christel Schaldemose (S&D). **Estonia:** Urmas Paet (Renew Europe); **Finland:** Alviina Alametsä (Greens/EFA); Heidi Hautala (Greens/EFA); Miapetra Kumpula-Natri (S&D); Sirpa Pietikäinen (EPP). **France:** François-Xavier Bellamy (EPP); Dominique Bilde (I&D); Nathalie Colin-Oesterlé (EPP); Arnaud Danjean (EPP); Geoffroy Didier (EPP); Agnes Evren (EPP); Sylvie Guillaume (S&D); Brice Hortefeux (EPP); Nadine Morano (EPP); Dominique Riquet (Renew Europe); Anne Sander (EPP). **Germany:** Alexandra Geese (Greens/EFA); Erik Marquardt (Greens/EFA); Angelika Niebler (EPP); Terry Reintke (Greens/EFA). **Greece:** Manolis Kefalogiannis (EPP); Stelios Kouloglou (GUE-NGL); Dimitrios Papadimoulis (GUE/NGL); Maria Spyraiki (EPP); Elissavet Vozemberg-Vrionidi (EPP). **Hungary:** Tamás Deutsch (EPP); Ádám Kósa (EPP). **Ireland:** Barry Andrews (ALDE); Deirdre Clune (NI); Ciarán Cuffe (Greens/EFA); Clare Daly (GUE/NGL); Frances Fitzgerald (EPP); Luke 'Ming' Flanagan (GUE/NGL); Billy Kelleher (Renew Europe); Seán Kelly (EPP); Grace O'Sullivan (Greens/EFA). **Italy:** Isabella Adinolfi (NI); Brando Benifei (S&D); Pierfrancesco Majorino (S&D); Aldo Patriciello (EPP); Patrizia Toia (S&D). **Lithuania:** Vilija Blinkeviciute (S&D). **Luxembourg:** Marc Angel (S&D); Charles Goerens (Renew Europe); Christophe Hansen (EPP); Tilly Metz (Greens, EFA); Isabel Wiseler-Lima (EPP). **Malta:** Roberta Metsola (EPP); Alfred Sant (S&D). **Netherlands:** Jeroen Lenaers (EPP); Annie Schreijer-Pierik (EPP). **Poland:** Elżbieta Lukacijewska (EPP); Jan Olbrycht (EPP). **Portugal:** Sara Cerdas (S&D); José Gusmão (GUE/NGL); Marisa Matias (GUE/NGL); Cláudia Monteiro de Aguiar (EPP); Manuel Pizarro (S&D). **Romania:** Cristian-Silviu Busoi (EPP); Marian-Jean Marinescu (EPP). **Slovakia:** Ivan Stefanec (EPP). **Slovenia:** Franc Bogovič (EPP); Milan Brglez (S&D); Klemen Grošelj (Renew Europe); Irena Joveva (ALDE); Romana Tomc (EPP); Milan Zver (EPP). **Spain:** Izaskun Bilbao Barandica (Renew

Europe); Rosa Estaräs Ferragut (EPP); Juan Fernando López Aguilar (S&D); Diana Riba i Giner (Greens-EFA); Ernest Urtasun (Greens/EFA). **Sweden:** Peter Lundgren (ECR).

EU DEVELOPMENTS

7 February: European Commission publishes report on the future of social protection



The European Commission has published a report into the future of social protection in the EU. The report was developed by a High-Level Group (HLG) on the future of social protection

and the welfare state, which was initiated at the end of 2021, as part of the European Pillar of Social Rights Action Plan.

The HLG was established to analyse the expected impact of “megatrends”, including demographic changes, the accompanying shrinking workforce and an ageing population, as well as transformations on the labour market and the digital and green transitions. Additionally, the emergence of new risks on the social protection and on welfare systems were explored.

The members of the group also examined the design and scope of social protection systems and the financing of social protection, presenting key strategic recommendations to both national and EU levels. As part of this, the HLG outlined how protection systems and the welfare state should be reinforced for the medium to long-term, towards 2030. The full report is available at:

<https://ec.europa.eu/social/BlobServlet?docId=26589&langId=en>

10 February: European Commission launches Public Consultation on EU Disability Card



The European Commission is currently developing the legislative proposal for the upcoming European Disability Card. After the Call for Evidence it launched last December, and a detailed survey, the Commission has now opened a 12-week public consultation. The questionnaire is available in all EU languages and in easy-to-read English. The responses will, in

turn, feed the impact assessment that will then serve as a basis for the future proposal, expected for the last quarter of 2023.

The consultation is open until 5 May 2023.

Find out more and respond to the questionnaire, here:

https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/13517-European-disability-card/public-consultation_en

14 February: European Parliament sets up new public health subcommittee



The European Parliament has voted to create a new permanent subcommittee for public health matters. In the Plenary session, MEPs set out the responsibilities and size of the new Public Health subcommittee, which will sit under the Committee on the Environment, Public Health and Food Safety (ENVI).

Subcommittees may be formed at the request of an already established standing committee, in the interests of this committee’s work, however, they cannot adopt legislative texts.

The subcommittee on public health will comprise 30 members and will deal with programmes and specific actions in the field of public health, pharmaceutical and cosmetic products, the European Medicines Agency, and the European Centre for Disease Prevention and Control. The ENVI committee remains responsible for examining and voting on legislative proposals. More information on the subcommittee is available at:

<https://www.europarl.europa.eu/news/en/press-room/20230210IPR74714/parliament-sets-up-new-public-health-subcommittee>

14 February: European Parliament adopts reports on political rights

The European Parliament has approved two reports, containing measures to strengthen the political rights of EU citizens living in another Member State of which they are not national (“mobile EU citizens”).

The reports (2021/0372(CNS) and 2021/0373(CNS)) set out the Parliament’s stance concerning two Directives proposed by the European Commission on the rights of mobile EU citizens to participate in the European and municipal elections.

The Parliament specifies that all EU citizens should have the right to vote “regardless of legal capacity”, whilst also including a provision stating that the legal capacity status decided by a citizen’s country of origin should not make them ineligible to stand as a candidate in elections to the European Parliament (providing the law in their country of residence does not prevent them).

In relation to the elections, the Parliament proposes that all measures to facilitate the right to vote to nationals with disabilities, should also be put in place for non-nationals EU citizens with disabilities. Additionally, it calls for the information provided to voters to comply with the accessibility requirements set in the European Accessibility Act, including in accessible formats. The full reports are available at:

[https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&reference=2021%2f0373\(CNS\)](https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&reference=2021%2f0373(CNS))

[https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&reference=2021%2f0372\(CNS\)](https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&reference=2021%2f0372(CNS))



POLICY WATCH

1 February: Special dementia panel organised at Finnish Parliament



Members of the national and regional working groups of people with dementia and their carers gathered at the Finnish Parliament on 1 February, to put questions to a panel of MPs. Whilst a lively discussion covered various topics regarding dementia, the most popular themes proved to be the role of carers and housing issues. The event was organised by the Alzheimer Society of Finland (Muistiliitto) and the Finnish Parliament Dementia Group (comprised of MPs interested in dementia issues).

This highly topical event coincided with the kick-off of election campaigns by political parties and candidates in Finland, as the country gets ready for parliamentary elections in April 2023.

7 February: OECD publishes end-of-life care report



The Organisation for Economic Cooperation and Development (OECD) has published a report examining how end-of-life care may be improved, including in the areas of workforce, quality,

funding and governance.

The report found that end-of-life care does not always reflect the wishes of the person and that, across OECD countries,

hospitals account for the place of death in more than 50% of cases deaths. Key findings of the report include:

- Too many people receive sub-par care in their last days or months of life, with access to services often being insufficient and unequal, especially at home
- Professionals often fail to discuss choices that provide people a dignified end of life
- Care provided at the end of life often fails to alleviate suffering, nor limit unnecessary treatments
- Costs at the end of life are high for both the public purse and families, while not necessarily delivering quality of life
- Putting end-of-life care higher in the policy agenda and implementing a more comprehensive set of policies would make the end of life a more meaningful and humane experience for people and their relatives.

The report also examines the subject in relation to a number of conditions, including dementia. The report identifies the growing number of persons living with dementia, as well as the specific challenges which arises in relation to providing appropriate care. The full report is available:

<https://www.oecd-ilibrary.org/sites/722b927a-en/index.html?itemId=/content/publication/722b927a-en>

14 February: Global Ageing Network launches Call to the Governments of the World on Long-term Care and Ageing

On 14 February 2023, the Global Ageing Network (GAN) issued a "Call to the Governments of the World on Long-term Care and Ageing" demanding urgent attention to and reform of long-term care systems for older people. For over a year, experts from around the world have been working on this document in response to the increasing risk of future inaccessibility and unaffordability of long-term care services, and at least half of all older adults expected to need long-term care services at some point in their lives. An increasing number of older people need daily, often demanding care, in part due to the increase in the number of people with dementia, but due to critical shortages of staff in social services.



The report stresses that the impact of issues arising from ageing populations in countries around the world, combined with declining numbers of carers and insufficient government support for services that older adults need to live well, demands immediate attention.

The Call to the Governments of the World on Long-term Care and Ageing contains not only a description of the major problems and current challenges of long-term care, an emphasis on the importance of providing care and support to older people as a guarantee of their fundamental right to live

with dignity, but also concrete directions for solutions and important principles.

It is being distributed and disseminated to social and health care ministries and other relevant stakeholders across all continents, including Europe.

The global expert group responsible for this report included: Jiří Horecký, president of the Association of Social Services, in the Czech Republic, Chairperson of the GAN and President of the European Ageing Network (EAN); Stuart Kaplan, CEO, Selfhelp Community Services in New York, NY; Dan Levitt, professor and CEO, KinVillage, Delta, British Columbia, Canada; Katie Smith Sloan, executive director, Global Ageing Network; Megan Davies, PhD, University of Basel and Maastricht University; Dr Freek Lapre, professor, TIAS Business School, Tilburg University, Netherlands; and Donald Macaskill, PhD, CEO, Scottish Care.

The GAN is an international network of leaders in ageing services, housing, research, technology and design from more than 60 countries all over the world. Find out more: <https://globalageing.org/>

The EAN groups more than 10,000 care providers in 26 European countries, aiming to improve quality of life for older persons and providing high quality housing, services and care. Find out more: www.ean.care

16 February: World Health Organization invites you to give feedback on its Global Campaign to Combat Ageism



The Global Campaign to Combat Ageism is an initiative supported by the 194 Member States of the World Health Organization (WHO) and is integral to the UN Decade of Healthy Ageing (2021–2030). The campaign aims to tackle ageism by changing how people think, feel and act towards age and ageing. The objectives of the campaign are:

- to generate an evidence base
- to raise awareness and build capacity – events, training programmes
- to build a global coalition to generate change – to improve data collection, share knowledge, and coordinate efforts.

The WHO is seeking feedback on this campaign. The Survey exists in five European languages:

English: <https://share.decadeofhealthyageing.org/ageism-haveyoursay>

French: <https://share.decadeofhealthyageing.org/ageism-haveyoursay-fr>

Spanish: <https://share.decadeofhealthyageing.org/ageism-haveyoursay-es>

Portuguese: <https://share.decadeofhealthyageing.org/ageism-haveyoursay-pt>

Russian: <https://share.decadeofhealthyageing.org/ageism-haveyoursay-ru>

It will be open until **8 March 2023**.

16 February: Netherlands launches large scale collaboration to improve diagnosis of dementia, as part of its National Dementia Strategy



**TIMELY
ACCURATE
PERSONALISED**

On 16 February 2023, as part of the Dutch National Dementia Strategy, a large-scale research consortium called “TAP-dementia” (Timely, Accurate and Personalized diagnosis of dementia) was launched. Researchers throughout the Netherlands will collaborate, through TAP-dementia, to improve the diagnosis of Alzheimer’s disease (AD) and other types of dementia.

With over 55 million people living with the condition worldwide, dementia is among the world’s largest healthcare challenges. Different brain diseases can cause dementia and identifying the specific disease underlying dementia can be a complex process. This is one of the reasons why it often takes years before a diagnosis is made. Sometimes no diagnosis is made at all and while the person knows they have dementia, they don’t know which type.

A good diagnosis is important, because it is the gateway to appropriate care and treatment. Knowing the cause of signs and symptoms is important for people with dementia and their families, so that they can then develop a better understanding of what to expect and how to manage things. An accurate diagnosis is also the starting point for developing effective treatment strategies. Thanks to the development of reliable biomarkers, the diagnosis of AD has improved considerably. TAP-dementia aims to improve scalability and accessibility of AD diagnosis, as well as other types of dementia, such as vascular dementia, frontotemporal dementia, and dementia with Lewy bodies.

Some individuals can have more than one form of dementia. “For this reason we focus on mixed pathology, or the co-occurrence of more than one brain disease in the same person.

Because we know this is very common”, says Professor Wiesje van der Flier, project lead of TAP-dementia.

Ten organisations have joined forces in TAP-dementia to complete five research projects. TAP-dementia will study how diagnoses fit best with the wishes and needs of patients and their families. Promising diagnostic tests for different types of dementia will be evaluated in clinical practice. Finally, TAP-dementia will develop novel tests, with the goal to refine the diagnosis and identify disease processes more precisely. In this way, the researchers plan to improve the diagnosis of AD and other types of dementia.

Within the consortium, people with dementia and their families play an important role. These people know the diagnostic trajectory better than anyone and they can help researchers understand where there is room for improvement. This group of will also help to ensure that researchers stay focused on the important issues and that study findings are subsequently applied in clinical practice.

TAP-dementia is a Dutch national consortium, led by Prof. van der Flier, scientific director of Alzheimer Center Amsterdam, Amsterdam UMC. The consortium includes five Alzheimer centres (Amsterdam UMC – location VUmc, Erasmus MC, University Maastricht, RadboudUMC, UMC Groningen), UMC Utrecht, Amsterdam UMC – location AMC, Vrije Universiteit Amsterdam, Elisabeth TweeSteden Ziekenhuis, Vilans and the Dutch Memory Clinic Network.

As part of the [National Dementia Strategy](#) 2021-2030, the Dutch Ministry of Health, Welfare and Sport has recommended to intensify research efforts on causes of dementia, diagnosis, young onset dementia, prevention, and innovative treatments of dementia. TAP-dementia is one of the consortia launched under the umbrella of the National Dementia Strategy, as part of Onderzoeksprogramma Dementie of ZonMW. More information can be found on the website (in Dutch):

<http://www.tap-dementia.nl/>

A short animation video (with English subtitles) can be viewed, here: https://www.youtube.com/watch?v=6Lq-RiP8_SE

17 February: Slovenian Ministry of Health presents new campaign Health Ambassadors

The Ministry of Health of Slovenia has launched a big new campaign to raise awareness around dementia, cancer and mental health, as well as to diminish the use of alcohol, cigarettes and addictive non-chemicals such as telephones, computers and video games, especially among young people in primary schools. Four celebrities have been chosen to be the faces of the campaign: including a pop singer, an actress who recently had breast cancer and a young “influencer”. In order to successfully promote a healthy lifestyle and key health risk factors in 2023, the Ministry of Health appointed celebrities from the fields of sports, culture and digital media to participate in creating positive stories around preventing the use of alcohol and tobacco among young people, de-stigmatisation of mental

health problems, dementia and awareness-raising activities regarding cancer prevention.

The goal of the Campaign is to promote a healthy life style, to raise awareness for prevention and to show that everyone can do something for their health. The first event was organised on 17 February, in Government protocol facilities, with the Minister of Health of the Republic of Slovenia, Dr Danijel Bešič Loredan (pictured, far right).

Štefanija Zlobec, President of Spominčica – Alzheimer Slovenija was in attendance, together with Tomaž Gržinič, who was introduced to the Minister as a former member of the European Working Group of People with Dementia (2017 to 2022) and as Spominčica’s ambassador for dementia. Those present were greeted by the Minister, and emphasised the importance of a healthy lifestyle in maintaining health.

The presence of many organisations, societies and associations at the event is a sign that a variety of stakeholders in different sections of society are interested and are ready to participate and support the campaign. The event was also fully supported by the media including TV channels.

Spominčica says it will continue to support the promotion of a healthy lifestyle of all age groups, and especially of dementia.



Pictured: (from right to left) Minister for Health of the Republic of Slovenia Dr Danijel Bešič Loredan, Tomaž Gržinič and Štefanija L. Zlobec

You
Tube

SUBSCRIBE

SCIENCE WATCH

25 January: New report jointly written by George Rook, living with young onset dementia, and Jacoba Huizenga, PhD candidate explores everyday experiences of living with dementia



A research report with an overview of everyday experiences of people living with dementia or Mild Cognitive Impairment (MCI) has been published, see <https://www.mdpi.com/1804610>

This scoping review aimed to explore the everyday life experiences, challenges and facilitators of individuals with dementia and MCI living at home. 58 qualitative studies were included. The review shows that the change from a clinical care focus to a broader focus on all aspects of everyday life opened rich insights into the insider's perspective of people living with dementia, but the question was: how to share this scientific publication with a broader audience?

Researcher Jacoba Huizenga shared this research report with George Rook, one of the Dementia Enquirers. She met him, together with other pioneers, during a mini internship for early career researchers, organised by Innovations in Dementia. George Rook read the paper and responded: "What a wonderful, interesting paper. You have brought together so much of what 'we' need to know in order to move support forward. I am going to recommend that all professionals involved in dementia and related social care read it." Together they produced an accessible version, specifically aimed at professionals. George Rook also wrote a foreword. This accessible version can be read here:

<https://www.internationalhu.com/research/publications/short-version-of-everyday-experiences-of-people-living-with-mild-cognitive-impairment-or-dementia-a>

1 February: Cochrane review analyses studies on cognitive stimulation, finding small benefits for people with mild-to-moderate dementia



In a systematic review article for the Cochrane library, a group of researchers led by Prof. Bob Woods at Bangor University have identified that cognitive stimulation programmes may have

small, short-term cognitive benefits for people with mild-to-moderate dementia.

Cognitive stimulation is a form of mental exercise that involves activities to stimulate thinking and memory, often delivered via group sessions. In their systematic review, Prof. Woods and colleagues surveyed the evidence from research studies looking at the efficacy of cognitive stimulation (CS) for people with dementia and their carers. In total, they found 37 studies involving 2766 participants with mild or moderate dementia, with an average age of 79 years. Most studies lasted around 10 weeks, with an average number of 20 CS sessions.

Overall, no negative results were reported from any studies. Participation in regular CS activities had a small beneficial effect on people with mild to moderate dementia. In 25 studies (corresponding to 1893 participants) which reported results of mini-mental state examination (MMSE) tests, an average difference of 1.99 points was found between people who took part in regular CS sessions, compared to those who did not. Studies also reported some improvements in communication, social interaction, mood and behaviour. However, overall participation in CS did not make much difference to carer's mood or anxiety levels. The authors also found evidence suggesting that cognitive benefits for people with dementia were greatest when group sessions occurred twice weekly or more, and when they were at the milder stages of dementia. Read a summary of the review, here:

<https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005562.pub3/abstract>

7 February: Expert consensus group prioritises outcome measures for Alzheimer's Disease, publishing their findings in the Alzheimer's and Dementia journal

On 7 February, the Alzheimer's and Dementia journal published a global inter-societal Delphi consensus on outcome measures for Alzheimer's disease (AD), co-authored by a group of experts including our Executive Director, Jean Georges.



As Alzheimer's disease (AD) progresses, people experience many different symptoms, ranging from memory problems to issues with language, social engagement and coordination. AD also affects quality of life, such as the ability to practice hobbies, or maintain relationships in the same way. Clinicians measure these outcomes, and the impact they have on patients using an array of tests and assessments. However, clinical studies and trials inconsistently use these outcome measures, making it hard to compare and interpret results. It is also unclear which are the most appropriate, robust and feasible measures to use in routine clinical practice.

To address these questions, a group of experts from many different backgrounds was convened, including patients, patient representatives, family doctors, nurses and healthcare professionals from across the globe. Chaired by Prof. Giovanni Frisoni (University of Geneva, Switzerland), this group used a Delphi process of voting to prioritise AD outcome measures for use in clinical practice when caring for patients who have symptomatic AD, particularly in the mild cognitive impairment, mild and moderate dementia stages. The list of outcomes was identified using a detailed, systematic review of the existing literature. Domains represented included cognitive abilities, functional abilities, behavioural and psychiatric symptoms, along with quality of life measures for patients or caregivers and family, among others.

Together, the group achieved consensus on prioritising defined outcomes for patients according to their stage of AD. Prioritised cognitive tests including the mini-mental state exam (MMSE) and Montreal Cognitive Assessment (MoCA), which was identified as a well-validated tool that is easy to administer. In the patient quality of life (QoL) domain, experts prioritised outcomes that measure the impact of AD on relationships, social contact and remaining active, which were all identified as important for the well-being of patients. These outcomes can be measured using tests such as QoL-AD, DEMQoL and EQ-5D-5L. The experts also prioritised global outcome measures, in which patients are interviewed along with their caregiver or family members. The highest-scoring outcome measure in this category was the Clinical Dementia Rating (CDR) scale, which is frequently used in clinical trials. The experts highlighted the importance of involving patients and caregivers in developing and determining priority outcome measures, stating that more work is needed to develop instruments that integrate easily into clinical routines.

Read the article below to see the full list of outcome measures:

<https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12945>

8 February: Study suggests that more research is needed to identify the major contributors to cognitive decline



A decline in cognitive functioning (which refers to a decline in the performance of mental abilities such as reasoning, planning, remembering, problem-solving, and understanding as age increases) is common even in individuals without

neurodegenerative diseases. Previous studies have identified many factors that are significantly associated with the level of cognitive functioning (e.g. genetics). However, to what extent

these contribute to the variation in the level and trajectory of decline in cognitive functioning remains unclear.

In a new study published in the journal PLOS ONE, a team of researchers led by Hui Zheng from Ohio University (Ohio, US) analysed data from 7,068 American adults, born between 1931 and 1941, in the 1996–2016 Health and Retirement Study. Researchers collected extensive information on factors (i.e. childhood health, nutrition, education, household wealth, household income, number of marriages, children, chronic diseases, smoking status, physical status, vigorous activity...) that could correlate and contribute to the level of cognitive functioning and the cognitive functioning trajectory from age 54 to 85.


The individual factors examined in the study accounted for 38% of the variation between participants in the level of cognitive functioning at age 54. Personal education was the biggest contributor to the population-level variation, followed by race, household wealth, household income, occupation, parental education and level of depression. The contributions of health behaviours (i.e. smoking, obesity and vigorous activity), childhood conditions, chronic diseases, gender, marital status and religion were small (less than 5%). Researchers also found that the variation in cognitive functioning between participants aged 54 was three times as large as the variation in the trajectory of decline in cognitive functioning over the next 30 years. In addition, age only explained 23% of the variation in cognitive functioning progression from age 54 to 85.

These findings reveal that more research is needed to identify the factors that determine and contribute to the rate of cognitive decline over age. Understanding why cognitive abilities are better and cognitive decline slower in some people is key to the development of medical treatments that target cognitive functioning.

Predictors of cognitive functioning trajectories among older Americans: A new investigation covering 20 years of age- and non-age-related cognitive change | PLOS ONE

20 February: New systematic review of proton pump inhibitor use and risk of dementia in older adults published in the journal touchREVIEWS in Neurology

Proton pump inhibitors (PPIs) are commonly used for gastroesophageal reflux disease. Previous studies have raised concerns about the impact of PPIs on cognition in older adults, but with a limited amount of evidence available to support this concern, a new systematic review has been conducted by authors Xiaoyi Gao, Zi Yi Shao, Noam Grysman, George T Grossberg.



It was published in the journal touchREVIEWS in Neurology on 20 February 2023.

The systematic review looked at relevant studies conducted between 2015 and 2022. Seventeen such studies were identified. Limitations to available research data included the fact that studies were mainly observational, used heterogeneous study methods and did not account for confounding variables such as B12 deficiency, *Helicobacter pylori* infection, and thyroid dysfunction. Overall, this review did not find a compelling association between PPI use and cognitive decline.

The review concluded that studies have overall demonstrated conflicting results regarding the association between long-term PPI use and cognitive decline, and that the extent of the impact of PPIs on cognitive functions remains controversial. Despite a variety of studies and sample sizes, the overall quality of evidence for PPIs' adverse effects on cognition is low, the authors state.

Future studies should take into account confounding factors and have a stringent study design, including the patient inclusion and exclusion criteria and study duration, they say, noting that more high-quality, long-term, controlled studies and investigations of purported pathophysiological mechanisms are needed. Read the article, here:

<https://touchneurology.com/alzheimers-disease-dementia/journal-articles/proton-pump-inhibitor-use-and-risk-of-dementia-in-older-adults-a-systematic-review/>

21 February: New study suggests a link between fructose and Alzheimer's disease



A recent study published in The American Journal of Clinical Nutrition suggests that a type of sugar called fructose could be a driver of Alzheimer's disease (AD).

An important aspect of survival is to assure enough food, water, and

oxygen. When threatened with the possibility of starvation, humans developed an instinct response that sent them foraging for food. Researchers at the US University of Colorado Anschutz Medical Campus indicated that the entire foraging response was set in motion by the metabolism of fructose whether it was eaten or produced in the body. The fructose induces insulin resistance and preserve glucose, source for immediate energy needs. Authors indicated that fructose could reduce metabolism in brain regions involved in higher cognitive functions.

Richard Johnson, first author of the study, called this survival response the "survival switch". He argued that if this "survival switch" is permanently on, this could lead to the overeating of

high-fat, sugary and salty food prompting excess fructose production. Although this pathway is beneficial at short-term, high levels of fructose could alter brain metabolism. A chronic and persistent reduction in brain metabolism might lead to progressive brain atrophy and neuron loss and cause degeneration of brain regions associated with AD.

Researchers recommended more studies on the role of fructose metabolism in AD to determine whether there is potential benefit in the prevention, management, or treatment of this disease.

<https://doi.org/10.1016/j.ajcnut.2023.01.002>

27 February: "Pad cultures: An ethnography of continence care and its consequences for people living with dementia during a hospital admission" published recently in journal Dementia

There is little research examining how continence care is organised and delivered to people living with dementia across an acute hospital admission, despite the prevalence of this patient population and their vulnerability within these settings. With this in mind, a



recent study was completed by Andy Northcott, Paula Boddington and Katie Featherstone from the Geller Institute of Ageing and Memory, University of West London. They observed the organisation and delivery of continence care to people living with dementia, in acute medical units and wards within three hospitals across England and Wales, over a period of 12 months. The resulting article was published in the journal Dementia.

The authors conclude that continence care for people living with dementia admitted to acute hospital wards is dominated by what they have termed "pad cultures", i.e. the everyday use of continence pads for patients living with dementia regardless of their continence status. While the organisational rationales for these approaches were clear, their consequences for people living with dementia, for staff, and for a wider population of older patients within these acute wards were significant. Their data, the authors note, suggests that independent and supportive continence care can have benefits for both people living with dementia and for staff in hospital wards.

Read the full study, here:

<https://journals.sagepub.com/doi/10.1177/14713012221116490>



Follow us on Twitter

Alzheimer's Society Annual Conference

Thursday 18 May 2023
Park Plaza Hotel London,
and Online

Registration open

Sponsors



Rothsay



MEMBERS' NEWS

4 February: Soap and real-life couple Bryan Murray and Una Crawford-O'Brien interviewed by Tommy Tiernan on Irish National Television



Actors Bryan Murray and Una Crawford O'Brien appeared on The Tommy Tiernan Show on the national Irish television station RTÉ on 4 February 2023. In an honest and open conversation, the pair - who are a couple in real life and on RTÉ soap Fair City - spoke in-depth about various aspects of

their lives, including their acting careers and their journey since Mr Murray's Alzheimer's diagnosis three years ago.

Mr Murray, a member of the Irish Dementia Working Group (IDWG), said RTÉ provides excellent support on set as he finds it challenging to retain lines from a script. Describing one particular moment, he said: "I had the key to the door, if you like. I had an earpiece that went all the way down my back into the back of my trousers. The person that I'm doing the scene with, after they're finished, I'd be fed the line that I'm next to say, and I got used to it and it was as easy as pie. It's the key in the door now, thank goodness."

He also said that Una Crawford O'Brien has been "an absolute bedrock" of support for him. "I don't know what I would have done for the last while without her but she has been fantastic right along the line of it and I'm incredibly grateful."

Bryan Murray and Una Crawford O'Brien shared their story publicly for the first time in August 2022. Ms Crawford O'Brien explained that they wanted "to let people know that it's not the end of the road for if you get a diagnosis of dementia, that you can keep going. You don't have to give up life just because you have dementia. You can get out there and you can work. More people might see that they can facilitate people who have it, in ways that they never thought of before." The interview is available to watch, here:

<https://www.rte.ie/player/series/the-tommy-tiernan-show/SI0000001918?epguid=IP10001177-07-0005>

Pictured: Bryan Murray and Una Crawford O'Brien on the Tommy Tiernan Show (Photo by RTÉ)

4 February: Model and Alzheimer Society of Ireland Ambassador Joanna Cooper appears on Irish national television programme "Ireland AM"

Model and The Alzheimer Society of Ireland (ASI) Ambassador Joanna Cooper appeared on Virgin Media Television's programme "Ireland AM" on 7 February 2023, where she discussed her mother Terri's dementia diagnosis, and her involvement in The ASI's "Denim Day for Dementia" campaign.

Ms Cooper, who opened up about her mum's diagnosis in January, in the hopes of helping others who have been impacted by dementia, said she was "blown away" by the response. She said that, through working with The ASI and talking about her experience on her online platforms, she has received a lot of support.

"I feel like dementia is not talked about enough. There's not really enough of a conversation around dementia, especially around young-onset dementia," she said.

She is encouraging everyone to get involved in The ASI's national Denim Day for Dementia on 3 March 2023, to help raise

vital funds for families living with dementia in Ireland. To register, go to: [alzheimer.ie](https://www.alzheimer.ie)

The interview is available to watch, here: <https://www.virginmediatelevision.ie/player/show/809/205420/0/Ireland-AM>



Pictured: ASI Ambassador Joanna Cooper on "Ireland AM" (Photo by Virgin Media Television)

7 February: Event "Masks" organised by Alzheimer Larissa



On 7 February 2023, the Volunteers of the Hellenic Alzheimer's Association (E.E.N.A.L.) in Larissa, introduced participants to the festive Triodion via the event "Masks". This event aimed at the mental empowerment of the beneficiaries, through the revival of Lenten customs. It was attended by 12 women of different cultural backgrounds, who heard about the future-proof history

of the Mask and its use in disguise. Then, with the volunteers' help, the women created their personal masks by using ecological materials and colours of their choice.

This was accompanied with an interactive discussion about the Triodion, the celebration of Smoky Thursday and the award of the best mask. The team admired everyone's masks and unanimously settled on the award going to Mrs Paraskevi, who is distinguished for her artistic skills. The participants enjoyed a variety of juices, hot tea and delicacies. The event ended with a photoshoot and with the singing of a Greek folk song: "These days have it" by Domna Samiou, related to the spirit of the Triodion.

9-12 February: 13th Panhellenic Conference of Alzheimer's Disease and 5th Mediterranean Conference on Neurodegenerative Diseases hosted by Panhellenic Federation of Alzheimer's Disease and Related Disorders and Alzheimer Hellas



The 13th Panhellenic Conference of Alzheimer's Disease and the 5th Mediterranean Conference on Neurodegenerative Diseases were held as a combined event, in Thessaloniki (Greece) from 9 to 12 February 2023. Covering every aspect of dementia, there were more than 300 presentations which were allocated in four different halls and as a hybrid event it attracted participants from all over the world.

In the first hall there were presentations covering mainly medical issues, such as new treatments and diagnostic tools and ongoing clinical trials. In the second hall many other health professionals could gain new knowledge about non-pharmacological interventions for patients and new neuropsychological tools that can add reliability and validity to the clinical assessment. In the third hall, services and methods for care of people with dementia and for their caregivers were presented. The 5th Mediterranean Conference was held in the fourth hall and hosted only presentations in English from well-known scientists in the field of dementia, covering many topics, such as new technologies, diagnostic tools and treatment proposals. Moreover, there were five workshops which offered useful and practical knowledge to the participants.

Besides that, on 8 February the #WhatsYourPlan workshop, given by Alzheimer's Disease International, was hosted at the venue, where selected participants from every country had the chance to get useful assistance on how to organise a national dementia plan or reorganise their existing national dementia plan.

It was four days full of new knowledge and new ideas in the field of dementia. The organisers would like to thank all the participants and the speakers for their huge efforts and they are looking forward to seeing everyone again at their next conference, which is going to be held in two years' time. The whole organisation of the conference was run by the staff of the Greek Alzheimer associations.

23 February: The Alzheimer Society of Ireland is awarded Triple Lock Certification by Charities Institute Ireland



The Alzheimer Society of Ireland (ASI) is thrilled to be accredited as a 2023 Triple Lock member by Charities Institute Ireland (CII).

Members of CII are given the Triple Lock Standard for exhibiting excellent practices in governance, fund-raising, and financial reporting. This certification further assures The ASI's dedication to excellence, transparency, and accountability to donors and stakeholders.

Commenting on the news, The ASI's Head of Fundraising, Mairead Dillon, said: "We are delighted to have been awarded the Triple Lock status by the Charities Institute Ireland (CII). This demonstrates our commitment to ensuring our donors and supporters can have trust and confidence in ASI and the work that we do to support those living with dementia in our communities." Visit the CII website to learn more about the Triple Lock Standard:

<https://www.charitiesinstituteireland.ie/>

23 February: Partners of the project "Genetic counselling in European universities: The case of neurodegenerative diseases" (GECONEU), including Alzheimer Hellas, meet in Heidelberg



The partners of the project "Genetic counselling in European universities: The case of neurodegenerative diseases" (GECONEU) recently gathered in Heidelberg (Germany) for their second transnational project meeting. The project's main aim is to

develop an online course for university students focusing on genetic counselling (GC). Also, Heidelberg University organised a hybrid symposium in the field of GC on neurodegenerative disorders. The symposium lasted for four hours and took place at the Network Aging Research (NAR), Heidelberg University. During the symposium, many experts presented their work on GC, including talks on: "The benefits from the announcement of ApoE results" by Magda Tsolaki; the "Clinical perspective of GC in dementia" by Lutz Frölich and Lucrezia Huser; "Crossroads of artificial intelligence and personal decision making" by Christian Schaaf and Beate Ditzen; and "Stakeholders' attitudes towards dementia risk testing and early diagnosis of Alzheimer's disease: insights from a cross-

cultural study" by Zumrut Alpinar Sencan. At the end, all participants had the opportunity to ask questions and discuss. Find out more about the project, here:

<http://www.genecounsel.eu/>

23 February: Alzheimer Bulgaria is making progress in its Erasmus+ funded DementiaCare project



Last year, Alzheimer Bulgaria started the project "DementiaCare", funded by the Erasmus+ programme in partnership with Turkey, Italy, Slovenia, the UK, Spain, and Portugal. The project duration is two years and DementiaCare focuses on the adoption of non-pharmacological intervention strategies, in particular on the use of art therapy, recognised as a technique capable of reducing the depressive and behavioural symptoms of the clinical picture and of improving the overall quality of life of a person with dementia.

DementiaCare proposes an innovative model, as it involves leading experts in the field of neurodegenerative diseases, in creating a highly specific curriculum based on the use of art therapy in the early stages of the disease. The project combines innovation with the satisfaction of an existing and neglected health need.

The project encourages the exchange of good practices, new methods of elaboration, delivery, and evaluation of programmes, and new multidisciplinary training approaches able to promote high levels of teaching and skills development among different institutions and universities.

So far, the partners have collected good practices and have defined the target groups and the participants. In each country, there was also a survey conducted for professionals working with people with dementia for state-of-the-art desktop analysis of the current use of "Art Therapy". The partners are currently working on the methodology development and the curriculum content such as determining modules and developing shape of modules and lecture notes for Learning, Teaching and Training Activities.

During the two upcoming Learning, Teaching and Training Activities in 2023 (in Ankara, Turkey and Florence, Italy), the first version and final versions of the designed modules and curriculum will be tested. Read more about the project and its launch:

<https://alzheimer-bg.org/en/launch-of-the-erasmus-project-dementiacare/>

LIVING WITH DEMENTIA

20 February: Věra Ryšavá, member of the European Working Group of People with Dementia, introduces herself and tells us why she wants to raise awareness of Alzheimer's disease



My name is Věra Ryšavá, I am 67 years old and already retired. I didn't know much about Alzheimer's disease until I was diagnosed two years ago. If I noticed any news in the press or media, it was about the advanced stages of the disease and it was not very pleasant. I didn't recognise any symptoms myself, but my girlfriend was worried about my sometimes slightly confused behaviour. After an examination by my doctor and the subsequent diagnosis: "You have Alzheimer's", my life collapsed. After this, I experienced an internal slump - depression - then a slow finding of the ground under my feet again.

Thanks to people in the Czech Alzheimer's Society, loved ones and friends, I am functioning as well as my health allows. There has been a change in my life values: I no longer dwell on things that may have bothered me before, and I know I cannot change them. I try to live actively in the present both in my social life and in my private life. I am trying to live a healthier lifestyle than I had been and I also decided to give the nod for an interview on Czech Television.

My initial fears about the interview gave way to a desire to show that people with early stage Alzheimer's are people who "function normally", feel joy, pain, fear like others and have a tremendous drive to keep living as self-sufficient a life as possible. I have to admit that I was worried about the reaction of those around me, people who know or have known me and had no idea that I have this disease. The reaction of the people around me was mostly positive, but I felt that some people didn't know how to treat me, and showed such shyness and inhibitions on their part. I realised that it was important to talk about this illness so that people would realise that if they or anyone close to them had any problems relating to cognitive function, not to overlook them and to consult a doctor. The earlier I detect this disease, the better chance I have of living a longer, if possible self-sufficient life, with my own active life, and "delaying my loss of self".

23 February: Irish Dementia Working Group member Frank Golden achieves lifelong dream of publishing a book

As a member of the Irish Dementia Working Group, Frank Golden has participated in numerous engagements and projects. Frank, who is 83 years old, recently achieved his lifelong goal of publishing a book. This is an achievement for anyone, but for someone living with Alzheimer's disease, it is truly remarkable.

Advocacy, Engagement and Participation Officer with The Alzheimer Society of Ireland Saoirse Kelly caught up with Frank Golden about his book "The Irish Job", which is set in 1920s Dublin. Here is what he said:

The crucial role of Intelligence in the Irish War of Independence, 1919 - 1921 is rarely highlighted. As my father worked very closely with Michael Collins, I grew up with stories about Collins' crucial, but necessarily unknown, intelligence role in the fight for Ireland's independence. The first draft consisted of 120,000 words! Way too many! And the research took several years - it was most important that I was accurate.

All of the groundwork had been completed and I was on about my fourth draft when I was diagnosed with Alzheimer's.

From my point of view, research was vital. This is not necessarily the case with fiction. But I would advise others writing a book to edit, edit, edit before having an independent person read your (nearly) final draft!

I have already begun "Book Two". In fact, that was planned to be the first. But some way through, I realised that a "prequel", The Irish Job, was needed.


Pictured: Frank Golden, member of Irish Dementia Working Group, with his book The Irish Job





DEMENTIA IN SOCIETY

27 January: New song about Alzheimer's disease called "Wall of Glass" is released with a video available on YouTube



On 27 January 2023, Swiss record label The Hana Road Music Group released a new song about Alzheimer's disease. The song, "Wall of Glass", is an autobiographical piece written by one of the label's songwriters and is performed by singer MĂLINA (Malina Muresan). The music video

is available on YouTube and the label has kindly included Alzheimer Europe's donation page.

At the end of the music video, there is a dedication "to everyone who has lost their memory and everyone who has lost a loved one to Alzheimer's disease".

Watch the video, on YouTube: <https://youtu.be/PTaLVpWZ27g>

The song is available to buy, in digital stores: <https://ffm.to/wallofglass>

6 February: Sporting Memories: A great day of reminiscing at first countywide event in Ireland



On 6 February, The Alzheimer Society of Ireland (ASI) hosted a first-time countywide Sporting Memories event, with Wexford GAA, in association with Wexford County Council. The Wexford County Board of the Gaelic Athletic Association or Wexford GAA is one of the 32 county boards of the GAA in Ireland and is responsible for Gaelic games in County Wexford.

Over 80 people came together for the event – including those living with dementia, their families, carers, GAA stars and members of local sporting communities – to recall some of the great sporting moments in County Wexford's history.

It was a wonderful day of reminiscing and re-engagement, which is what Sporting Memories is all about. An awareness and support programme, Sporting Memories involves remembering and discussing sports to help improve health and well-being, particularly for people with dementia. Sporting Memories can help empower a person with dementia to re-engage in their local sporting community, which once played a huge role in their lives. Reminiscence is particularly important for people living with dementia, as remembering can instil a sense of competence and confidence, which can make people feel empowered.

Community Engagement Manager with The ASI Cathryn O'Leary said: "A resounding success, the first-time Sporting Memories event saw the power of sport bring together people young and old, especially those living with dementia and their families. This was a wonderful collaboration between agencies and The ASI appreciates the support from Wexford GAA, particularly the Health and Wellbeing Committee, Slainte Care and Wexford County Council."


NEW PUBLICATIONS AND RESOURCES

23 February: Personal initiative on Smart Home Tech and Alzheimer's disease provides tips and experiences in available technology

Recently, a new website with resources and learnings on smart home technology that can be used to support people living with Alzheimer's disease has been published. While home automation and similar tools are readily available, there seems to be a lack of understanding on how they can positively help with managing family members with Alzheimer's disease and enabling new solutions.

If you're new to the smart home world, this website gives you the information needed for your first steps and gets you started on your journey to make everyday life smarter while simplifying things for those who care for them at home or remotely.

<https://www.alzheimerstech.com>

 Alzheimer's & Technology



EDUCATION

28 February: Workshop on Biomarkers for Neurodegenerative Diseases taking place at BarcelonaBeta Brain Research Centre in May - Register before 24 March!

barcelonaBeta
BRAIN RESEARCH CENTER

A workshop is planned to take place from 15 to 19 May 2023, at BarcelonaBeta Brain Research Centre, with the aim of providing a comprehensive overview of the dynamic field of biomarkers for neurodegenerative diseases with a focus on Alzheimer's disease. Biomarkers are

increasingly required for effective research into neurodegenerative diseases. They are critical for diagnosis,

disease monitoring and will be key for measuring target engagement of disease modifying therapies.

PhD students working in the field of neurodegeneration require a working knowledge of a range of biomarkers to correctly interpret scientific literature and to design and conduct successful and ambitious research studies.

BarcelonaBeta Brain Research Center, University College London, and University of Gothenburg are leading international centres with complementary expertise in fluid and imaging biomarkers. This collaboration would be expected to strengthen the quality of biomarker training across the different institutions and beyond, as well as fostering new research collaborations and providing delegates with outstanding networking opportunities.

Registrations close on **24 March 2023**.

Find our more and register, here:
<https://www.barcelonabeta.org/en/community/events/6th-workshop-biomarkers-neurodegenerative-diseases>

AE CALENDAR 2023

Date	Meeting	AE representative
1-2 March	HMA/EMA multi-stakeholder workshop on medicines shortages	Angela
3 March	EMA joint meeting of Patients' and Consumers' and Healthcare Professionals' Working Parties	Angela
7 March	European Economic and Social Committee hearing on "Towards a European Health Union and European Global Health Strategy fully inclusive of persons with disabilities"	Jean
7 March	Consultation with the EWGPWD about the ADIS project	Dianne, Ana, Soraya and Daphné
13 March	PRIME project webinar: how do we model PRIME in mice?	Angela
14 March	Second consultation of the eBRAIN-Health PPAG	Daphné and Dianne
16 March	Interim review meeting of RECOGNISED project	Angela
16-17 March	AI-Mind General Assembly Meeting (Zurich, Switzerland)	Cindy
20-21 March	Alzheimer Europe Board (Brussels, Belgium)	AE Board and staff
21 March	European Parliament lunch debate "Dealing with behavioural and psychological symptoms in dementia care" (Brussels, Belgium)	AE members, sponsors and staff
21 March	Alzheimer Europe Company Round Table (Brussels, Belgium)	AE members, sponsors and staff
21-22 March	European Dementia Carers Working Group Meeting (Brussels, Belgium)	Dianne, Ana, Soraya and Daphné
22 March	Public Affairs Meeting (Brussels, Belgium)	AE members and staff
28-29 March	Data Saves Lives Training Bootcamp (Lisbon, Portugal)	Dianne
28 March-1 April	AD/PD Conference (Gothenburg, Sweden)	Jean

CONFERENCES 2023

Date	Meeting	Place
23-25 March	17 th World Congress on Controversies in Neurology (CONy), https://cony.comtecmed.com/supporting-partners/	Dubrovnik, Croatia
29-30 March	Dementia research conference 2023, https://www.bsms.ac.uk/about/events/2023/03-29-dementia-research-conference-2023.aspx	Online
17-20 April	AAIC Neuroscience Next, https://www.alz.org/neuroscienext/overview.asp	Online
18 May	Alzheimer's Society annual conference, https://www.alzheimer-europe.org/node/236625	London, UK and online
23 May	5 th European Parliament of Persons with Disabilities, "Building an inclusive future for persons with disabilities in the EU", https://www.edf-feph.org/5th-european-parliament-of-persons-with-disabilities/	Brussels, Belgium
14-16 June	31 st European Social Services Conference: Advancing Social Services The role of technology in promoting autonomy and inclusion, European Social Services Conference (essc-eu.org)	Malmö, Sweden
29 June-2 July	2023 IPA International Congress on "Better Mental Health for Older People", https://www.ipa-online.org/2023	Lisbon, Portugal
1-4 July	9 th EAN Congress - Budapest 2023: Neurology Beyond the Big Data, www.ean.org	Budapest, Hungary
15-19 October	WCN 2023 - The XXVI World Congress of Neurology, https://wcn-neurology.com/	Montreal, Canada
16-18 October	33 rd Alzheimer Europe Conference, "New opportunities in dementia care, policy and research", www.alzheimer-europe.org/conference	Helsinki, Finland

Contact Alzheimer Europe:

Alzheimer Europe: 14, rue Dicks (L-1417), Luxembourg; info@alzheimer-europe.org; www.alzheimer-europe.org

Alzheimer Europe Board:

Chairperson: Maria do Rosário Zincke Dos Reis (Portugal); Vice-Chairperson: Charles Scerri (Malta); Honorary Secretary: Mario Possenti (Italy); Honorary Treasurer: Marco Blom (Netherlands). Members: Stefanie Becker (Switzerland), René Friederici (Luxembourg), Lorène Gilly (France), Andy Heffernan (Ireland), Martina Mátlová (Czech Republic), Mary-Frances Morris (United Kingdom), Chris Roberts, Chairperson of the European Working Group of People with Dementia (United Kingdom), Katariina Suonu (Finland), Jochen René Thyrian (Germany).

Alzheimer Europe Staff:

Executive Director: Jean Georges; Communications Officer: Kate Boor Ellis; Conference and Event Coordinator: Gwladys Guillory; Director for Projects: Dianne Gove; Project Communications Officer: Christophe Bintener; Project Officers: Cindy Birck, Angela Bradshaw, Ana Diaz; Daphné Lamirel, Soraya Moradi-Bachiller; Policy Officer: Owen Miller; Finance Officer: Stefanie Peulen; Administrative Assistants: Cristina Pencea, Grazia Tomasini.

33rd Alzheimer Europe Conference

New opportunities in dementia care, policy and research

Helsinki, Finland

16 - 18 October 2023 #33AEC

www.alzheimer-europe.org/conferences

